分子靶向药物与肿瘤
Molecular Targeted Drugs and Tumors
摘要: 依据已知肿瘤发生中涉及的异常分子或基因，设计针对这些特定分子和基因靶点的药物，选择性杀伤肿瘤细胞，这种治疗方法称为肿瘤的分子靶向治疗。目前分子靶向药物用于治疗乳腺癌、非小细胞肺癌、结直肠癌以及淋巴瘤、白血病等恶性肿瘤已取得令人瞩目的疗效。针对现有的治疗恶性肿瘤的分子靶向药物的作一综述。
Abstract: According to the abnormal molecules or genes involved in the occurrence of the tumor, the drugs targeting these specific molecules and gene targets are designed, which are targeted to the tumor cells. This method of treatment is known as the molecular targeted therapy of tumor. At present, molecular targeted agents are used to treat breast cancer, non-small cell lung cancer, colorectal cancer, lymphoma, leukemia and other malignant tumors. The curative effect of these malignant tumors has been improved significantly. Molecular targeted agents for the treatment of malignant tumors will be described in this review.
文章引用：夏君燕, 朱平, 伍学强. 分子靶向药物与肿瘤[J]. 世界肿瘤研究, 2015, 5(4): 65-73. http://dx.doi.org/10.12677/WJCR.2015.54010

参考文献

[1] Perez, E.A., Suman, V.J., Davidson, N.E., et al. (2006) HER2 Testing by Local Central and Reference Laboratories in Specimens from the North Central Cancer Treatment Group N9831 Inter Group Adjuvant Trial. Journal of Clinical Oncology, 24, 3032-3038.
http://dx.doi.org/10.1200/JCO.2005.03.4744
[2] 安富荣. 曲妥珠单抗治疗转移性乳腺癌研究进展[J]. 中国肿瘤生物治疗杂志, 2002, 9(4): 70-72.
[3] Rugo, H., Kaufman, P., Tan-Chiu, E., et al. (2008) Survival of Patients with HER-2(+)Metastatic Breast Cancer and Use of Trastuzumab Following Progression: Analysis of registHER. The 31st San Antonio Breast Cancer Symposium Proceedings, San Antonio, 10-14 December 2008. http://www.researchgate.net/publication/273894156_Survival_of_patients_with_HER2_metastatic_breast_
cancer_and_use_of_trastuzumab_following_progression_analysis_of_RegistHER
[4] Procter, M., Surer, T., de Azambuja, E., et al. (2010) Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. Journal of Clinical Oncology, 28, 3422-3428.
[5] Tan-Chiu, E., Yothers, G., Romond, E., et al. (2005) Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, with or without Trastuzumab as Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: NSABP B-31. Journal of Clinical Oncology, 23, 7811-7819.
[6] Russell, S.D., Blackwell, K.L., Lawrence, J., et al. (2010) Independent Adjudication of Symptomatic Heart Failure with the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials. Journal of Clinical Oncology, 28, 3416-3421.
[7] Slamon, D., Eiermann, W., Robea, N., et al. (2009) Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC->T) with Doxornbicin and Cyclophosphamide Followed by Doeetaxel and Trastuzumab (AC->TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in HER2 Neu-Positive Early Breast Cancer Patients: BCIRG 006 Study. Cancer Research, 69, 62.
[8] Joensuu, H., Bono, P., Kataja, V., et al. (2009) Fluorouacil, Epirnbicin, and Cyclophosphamide with Either Doeetaxel or Vinorelbine, with or without Trastuzumab, as Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial. Journal of Clinical Oncology, 27, 5685-5692.
[9] De, P. and Leyland-Jones, B. (2005) Whither HER2-Related Therapeutics? Journal of Clinical Oncology, 28, 1091- 1096.
[10] Agus, D.B., Gordon, M.S., Taylor, C., et al. (2005) Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients with Advanced Cancer. Journal of Clinical Oncology, 23, 2534-2543.
[11] Lin, N.U., Carey, L.A., Liu, M.C., Younger, J., Come, S.E., Ewend, M., et al. (2008) Phase II Trail of Lapatinib for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology, 26, 1993-1999.
http://dx.doi.org/10.1200/JCO.2007.12.3588
[12] Kaufman, B., Trudeau, M., Awada, A., Blackwell, K., Bachelot, T., Salazar, V., et al. (2009) Lapatinib Momotherapy in Patients with HER2-Overexpressing Relapsed or Refractory Inflammatory Breast Cancer: Final Results and Survival of the Expanded HER2+ Cohort in EGF103009, a Phase II Study. The Lancet Oncology, 10, 581-588.
http://dx.doi.org/10.1016/S1470-2045(09)70087-7
[13] Gomez, H.L., Doval, D.C., Chzvez, M.A., Ang, P.C.-S., Aziz, Z., Nag, S., et al. (2008) Efficacy and Safety of Lapatinib as First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 26, 2999-3005.
http://dx.doi.org/10.1200/JCO.2007.14.0590
[14] Jagiello-Gruszfeld, A., Tjulandin, S., Dobrovolsksys, N., Ma-nikhas, A., Pienkowski, T., DeSilvio, M., et al. (2010) A Single-Arm Phase II Trial of First-Line Paclitaxel in Combi-nation with Lapatinib in Her2-Overexpressing Metastatic Breast Cancer. Oncology, 79, 129-135.
http://dx.doi.org/10.1159/000318043
[15] Zhou, X., Cella, D., Cameron, D., Amonkar, M.M., Segreti, A., Stein, S., et al. (2009) Lapatinib plus Capecitabine versus Capecitabine Alone for HER2+ (ErbB2) Metastatic Breast Cancer: Quality-of-Life Assessment. Breast Cancer Research and Treatment, 117, 577-589.
http://dx.doi.org/10.1007/s10549-009-0310-8
[16] Stoniolo, A.M., Pegram, M.D., Overmoyer, B., Silverman, P., Peacock, N.W., Jones, S.F., et al. (2008) Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combi-nation with Trastumab in Patients with Advance ErbB2- Positive Breast Cancer. Journal of Clinical Oncology, 26, 3317-3323.
http://dx.doi.org/10.1200/JCO.2007.13.5202
[17] Hennessy, B.T., Lu, Y.L., Poradosu, E., Yu, Q.H., Yu, S.X., Hall, H., et al. (2007) Pharmacodynamic Markers of Perifosine Efficacy. Clinical Cancer Research, 13, 7421.
http://dx.doi.org/10.1158/1078-0432.CCR-07-0760
[18] Ghayad, S.E., Vendrell, J.A., Larbi, S.B., Dumontet, C., Bieche, I. and Cohen, P.A. (2010) Endocrine Resistance Associated with Activated ErbB System in Breast Cancer Cells Is Reversed by Inhibiting MAPK or PI3K/Akt Signaling Pathways. International Journal of Cancer, 126, 545-562.
http://dx.doi.org/10.1002/ijc.24750
[19] Sawyers, C.L. (2003) Will mTOR Inhibitors Make It as Cancer Drugs? Cancer Cell, 4, 343-348.
http://dx.doi.org/10.1016/S1535-6108(03)00275-7
[20] FRYDW (1999) Inhibition of the Epidermal Growth Factor Receptor Family of Tyrosine Kinases as an Approach to Cancer Chemotherapy: Progression from Reversible to Irreversible Inhibitors. Pharmacology & Therapeutics, 82, 207- 218.
http://dx.doi.org/10.1016/S0163-7258(98)00050-3
[21] 王洋, 梁岳培. 抗VEGF和抗EGFR靶向治疗非小细胞肺癌的研究进展[J]. 临床医学工程, 2011, 18(2): 312-314.
[22] Hirsch, F.R., Varella-Garcia, M., Bunn Jr., P.A., Di Maria, M.V., Veve, R., Bremnes, R.M., et al. (2003) Epidermal Growth Factor Receptor in Non-Small-Cell Lung Car-cinomas: Correlation between Gene Copy Number and Protein Expression and Impact on Prognosis. Journal of Clinical Oncology, 21, 3798-3807.
http://dx.doi.org/10.1200/JCO.2003.11.069
[23] Shi, Y., Au, J.S., Thongprasert, S., Srinivasan, S., Tsai, C.M., Khoa, M.T., et al. (2014) A Prosective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). Journal of Thoracic Oncology, 9, 154-162.
http://dx.doi.org/10.1097/JTO.0000000000000033
[24] Kris, M.G., Johnson, B.E., Kwiatkowski, D.J., Iafrate, A.J., Wistuba, I.I., Aronson, S.L., et al. (2011) Identification of Driver Mutations in Tumor Specimens from 1,000 Pa-tients with Lung Adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology, 29, abstr CRA7506.
[25] Mok, T.S., Wu, Y.L., Thongrasert, S., Yang, C.H., Chu, D.T., Saijo, N., et al. (2009) Gefitinib or Carboplatin-Pacli- taxel in Pulmonary Adenocarcinoma. The New England Journal of Medicine, 361, 947-957.
http://dx.doi.org/10.1056/NEJMoa0810699
[26] Shi, Y.K., Zhang, L., Liu, X.Q., Zhou, C.C., Zhang, L., Zhang, S.C., et al. (2013) Icotinib versus Gefitinib in Previously Treated Advanced Non-Small-Cell Lung Cancer (ICOGEN): A Randomised, Double Blind Phase 3 Non-Infe- riority Trail. The Lancet Oncology, 14, 953-961.
http://dx.doi.org/10.1016/S1470-2045(13)70355-3
[27] Kelleher, F.C. and McDermott, R. (2010) The Emerging Pathogenic and Therapeutic Importance of the Anaplastic Lymphoma Kinase Gene. European Journal of Cancer, 46, 2357-2368.
http://dx.doi.org/10.1016/j.ejca.2010.04.006
[28] Kim, D.W., Ahn, M.J., Shi, Y., De Pas, T.M., Yang, P.-C., Riely, G.J., et al. (2012) Results of a Global Phase II Study with Crizotinib in Advanced ALK-Positive Non-Small-Cell Lung Cancer (NSCLC). Journal of Clinical Oncology, 30, abstr 7533.
[29] Khorana, A.A., Ryan, C.K., Cox, C., Eberly, S. and Sahasrabudhe, D.M. (2003) Vascular Endothelial Growth Factor, CD68, and Epidermal Growth Factor Receptor Expression and Survival in Patients with Stage II and Stage III Colon Carcinoma: A Role for the Host Response in Prognosis. Cancer, 97, 960-968.
http://dx.doi.org/10.1002/cncr.11152
[30] Hebbar, M., Wacrenier, A., Desauw, C., Romano, O., Cattan, S., Triboulet, J.P. and Pruvot, F.R. (2006) Lack of Usefulness of Epidermal Growth Factor Receptor Expression Determination for Cetuximab Therapy in Patients with Colorectal Cancer. Anti-Cancer Drug, 17, 855-857.
http://dx.doi.org/10.1097/01.cad.0000217425.44584.9f
[31] Schmoll, H.J., Cartwright, T., Tabemero, J., Nowacki, M.P., Figer, A., Maroun, J., et al. (2007) Phase III Trail of Capecitabine plus Oxaliplatin as Adiuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients. Journal of Clinical Oncology, 25, 102-109.
http://dx.doi.org/10.1200/JCO.2006.08.1075
[32] 张晓东. 结直肠癌分子靶向治疗的进展[J]. 医学综述, 2009, 15(14): 2122-2123.
[33] Jonker, D.J., O’Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.-J., et al. (2007) Cetuximab for the Treatment of Colorectal Cancer. The New England Journal of Medicine, 357, 2040-2048.
http://dx.doi.org/10.1056/NEJMoa071834
[34] Bokemeyer, C., Bondarenko, I., Hartmann, J.T., De Braud, F.G., Volovat, C., Nippgen, J., Stroh, C., Celik, I. and Koralewski, P. (2008) KRAS Status and Efficacy of First-Line Treat-ment of Patients with Metastatic Colorectal Cancer with FOLFOX with or without Cetuximab: The OPUS Experience (Abstract). Journal of Clinical Oncology, 26, 4000.
[35] Cheng, L., Eng, C., Nieman, L.Z., Kapadia, A.S. and Du, X.L. (2011) Trends in Colorectal Cancer Incidence by Anatomic Site and Disease Stage in the United States from 1976 to 2005. American Journal of Clinical Oncology, 34, 573- 580.
http://dx.doi.org/10.1097/COC.0b013e3181fe41ed
[36] 万德森, 刘晖. 第十三届世界胃肠道肿瘤大会: 贝伐单抗治疗结直肠癌新进展[J]. 肿瘤研究与临床, 2012, 24(1): 1-3.
[37] 万德森. 贝伐单抗在转移性结直肠癌治疗中的应用[J]. 中国肿瘤临床, 2009, 36(23): 1374-1376.
[38] Sunakawa, Y., Furuse, J., Okusaka, T., Ikeda, M., Nagashima, F., Ueno, H., et al. (2013) Regorafenib in Japanese Patients with Solid Tumors: Phase I Study of Safety, Efficacy, and Pharmacokinetics. Investigational New Drugs, 32, 104-112.
http://dx.doi.org/10.1007/s10637-013-9953-8
[39] 焦力, 王书杰, 庄俊玲, 赵永强, 周道斌, 许莹, 韩冰, 张薇, 段明辉, 邹农, 朱铁楠, 沈悌. 亚砷酸和全反式维甲酸对急性早幼粒细胞白血病疗效和副作用的比较[J]. 中国医学科学院学报, 2009, 31(5): 555-558.
[40] Pfreundschuh, M., Trtimper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., et al. (2006) CHOP-Like Chemotherapy plus Rituximab versus CHOP-Like Chemotherapy Alone in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma: A Randomised Controlled Trial by the Mab Thera Intemational Trial (MInT) Group. The Lancet Oncology, 7, 379-391.
http://dx.doi.org/10.1016/S1470-2045(06)70664-7
[41] Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., et al. (2005) Long-Term Results of R-CHOP Study in the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Study by the Groupe d’Etude des Lymphomes de I’Adulte. Journal of Clinical Oncology, 23, 4117-4126.
http://dx.doi.org/10.1200/JCO.2005.09.131
[42] Peyrade, F., Jardin, F., Thieblemont, C., Thyss, A., Emile, J.-F., Castaigne, S., et al. (2011) Attenuated Immunochemotheragy Regimen (R-miniCHOP) in Elderly Patients Older than 80 Years with Diffuse Large B-Cell Lymphoma: A Multicenter Single-Arm Phase 2 Trail. The Lancet Oncology, 12, 460-468.
http://dx.doi.org/10.1016/S1470-2045(11)70069-9
[43] Tan, D. and Horning, S.J. (2008) Follicular Lymphoma: Clinical Features and Treatment. Hematology/Oncology Clinics of North America, 22, 863-882.
http://dx.doi.org/10.1016/j.hoc.2008.07.013
[44] Czuezman, M.S., Grillo-LoPez, A.J., White, C.A., Saleh, M., Gordon, L., LoBuglio, A.F., Jonas, C., Klippenstein, D., Dallaire, B. and Varns, C. (1999) Treatment of Patients with Low Grade B Cell Lymphoma with the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Che-motherapy. Journal of Clinical Oncology, 17, 268-276.
[45] Du, J.M., Yang, H., Guo, Y.J. and Ding, J.P. (2009) Structure of the Fab Fragment of Therapeutic Antibody of Atumumab Provides Insights into the Recognition Mechanism with CD20. Molecular Immunology, 46, 2419-2423.
http://dx.doi.org/10.1016/j.molimm.2009.04.009
[46] O’rien, S.G., Guilhot, F., Goldman, J.M., et al. (2008) In-ternational Randomized Study of Interferon Reigns STl571 (IRIS) 7-Year Follow-Up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (IM). Blood, 112, abstr 186.
[47] 王建祥, 黄晓军, 吴德沛, 胡建达, 刘霆, 胡豫, 等. 中国15家医院慢性粒细胞白血病发病状况及目前诊断治疗模式调查分析[J]. 中华血液学杂志, 2009, 30(11): 721-725.
[48] Jiang, Q., Xu, L.P., Liu, D.H., Liu, K.-Y., Gale, R.P., Zhang, M.-J., et al. (2013) Imatinib Results in Better Outcomes than HLA-Identical Sibling Transplants in Young Persons with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia. Leukemia, 27, 2410-2413.
http://dx.doi.org/10.1038/leu.2013.159
[49] 黄晓军. 慢性髓性白血病的过去、现在和未来[J]. 中华血液杂志, 2014, 35(2): 89-91.

为你推荐